What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders

• In late June 2026, Neurocrine Biosciences was removed from the Russell 1000 Dynamic Index, even as analysts highlighted ongoing strength in INGREZZA sales and improved profit outlook.
• Fresh Phase 3 and real-world data for CRENESSITY in congenital adrenal hyperplasia added clinical depth but kept investor focus squarely on near-term commercial execution for INGREZZA and the emerging rare disease franchise.
• We’ll now examine how stronger INGREZZA sales momentum and guidance optimism may reshape Neurocrine Biosciences’ existing investment narrative.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Neurocrine Biosciences Investment Narrative Recap

To own Neurocrine Biosciences, you need to be comfortable with a story centered on INGREZZA’s commercial performance while the rare disease portfolio scales up. The removal from the Russell 1000 Dynamic Index does not materially change the key near term catalyst, which is continued INGREZZA sales execution and any guidance updates, or the biggest current risk, which is concentration in a few products amid payer pressure and potential pricing headwinds.

In that context, the fresh ENDO 2026 data for CRENESSITY in congenital adrenal hyperplasia look most relevant. They strengthen the medical case for CRENESSITY across both common and rarer CAH subtypes, but they keep the spotlight on how effectively Neurocrine can convert this clinical profile into durable reimbursement, formulary wins, and real world uptake alongside INGREZZA driven earnings.

Yet beneath the headline strength in INGREZZA, investors should also be aware of growing payer scrutiny and the possibility that...

Read the full narrative on Neurocrine Biosciences (it's free!)

Neurocrine Biosciences' narrative projects $5.1 billion revenue and $1.5 billion earnings by 2029.

Uncover how Neurocrine Biosciences' forecasts yield a $192.88 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Some analysts were already very optimistic, penciling in about US$6.4 billion of revenue and US$2.7 billion of earnings by 2029, yet the latest index removal and questions about CRENESSITY reimbursement show how those bullish expectations and the concentration risk around a few drugs could look very different once new information is fully reflected in the numbers.

Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth just $192.88!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Neurocrine Biosciences research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com